Details of Disease

General Information of Disease (ID: DISXHWCS)

• Disease Name: Fallopian tube cancer
• Synonyms: tumour of the fallopian tube; tumor of the fallopian tube; tumor, fallopian tube, malignant; tubal cancer; neoplasm, fallopian tube, malignant; malignant tumour of the fallopian tube; malignant tumour of fallopian tubes; malignant tumour of fallopian tube; malignant tumor of the fallopian tube; malignant tumor of fallopian tubes; malignant tumor of fallopian tube; malignant tubal tumour; malignant tubal tumor; malignant neoplasm of uterine tube; malignant neoplasm of the fallopian tube; malignant neoplasm of fallopian tube; malignant fallopian tube tumour; malignant fallopian tube tumor; malignant fallopian tube neoplasm; fallopian tube malignant tumour; fallopian tube malignant tumor; fallopian tube malignant neoplasm; fallopian tube cancer; cancer of fallopian tubes; cancer of fallopian tube
• Disease Class: 2C74: Fallopian tube cancer
• Definition: A primary or metastatic malignant neoplasm that affects the fallopian tube. Representative examples include carcinoma, carcinosarcoma, and leiomyosarcoma.
• Disease Hierarchy:
  DIST2NIJ: Gynecologic cancer
  DISAT1Z9: Advanced cancer
  DISHMMF2: Fallopian tube neoplasm
  DISXHWCS: Fallopian tube cancer
• ICD Code:
  ICD-11: ICD-11: 2C74
  ICD-10: ICD-10: C57.0
  Expand ICD-11: '2C74
  Expand ICD-10: 'C57.0
• Disease Identifiers:
  MONDO ID: MONDO_0002158
  UMLS CUI: C0153579
  MedGen ID: 102276
  Orphanet ID: 180242
  SNOMED CT ID: 363444001

Drug-Interaction Atlas (DIA) of This Disease

This Disease is Treated as An Indication in 2 Approved Drug(s)

Drug Name	Drug ID	Highest Status	Drug Type	REF
Bevacizumab	DMSD1UN	Approved	Monoclonal antibody	[1]
Niraparib Tosylate	DMLPSWQ	Approved	Small molecular drug	[2]

This Disease is Treated as An Indication in 16 Clinical Trial Drug(s)

Drug Name	Drug ID	Highest Status	Drug Type	REF
AL3818	DM3WP0N	Phase 3	NA	[3]
Pelareorep	DM4WCF9	Phase 3	NA	[4]
TRC105	DM1874J	Phase 3	Monoclonal antibody	[5]
EGEN-001	DM6L5TR	Phase 2	NA	[6]
Hu3S193	DMKTGER	Phase 2	NA	[7]
Rebmab-100	DM2CJ4O	Phase 2	Antibody	[8]
DPX-survivac cancer vaccine	DMOVQS4	Phase 1/2	NA	[3]
COTI-2	DM6K3JQ	Phase 1	NA	[3]
DMUC-5754A	DMCT4BA	Phase 1	Antibody	[9]
Hu-CART meso cells	DM9VB4I	Phase 1	CAR T Cell Therapy	[10]
MCY-M11	DMAESQI	Phase 1	CAR-PBMC Cell therapy	[11]
MOv19-BBz CAR T cells	DMYH98H	Phase 1	CAR T Cell Therapy	[12]
Navicixizumab	DMZ2G69	Phase 1	NA	[3]
OC-L vaccine	DM8JNBF	Phase 1	NA	[13]
Prolanta	DMLKF3H	Phase 1	NA	[3]
PTC596	DMI24V7	Phase 1	NA	[3]

Molecular Interaction Atlas (MIA) of This Disease

This Disease Is Related to 1 DTT Molecule(s)

Gene Name	DTT ID	Evidence Level	Mode of Inheritance	REF
MUC16	TTC1PS3	Limited	Biomarker	[14]

This Disease Is Related to 2 DOT Molecule(s)

Gene Name	DOT ID	Evidence Level	Mode of Inheritance	REF
BARD1	OTTC0Z9Y	moderate	Genetic Variation	[15]
BRCA1	OT5BN6VH	Strong	Genetic Variation	[16]

References

• [1] OCEANS: a randomized, double-blind, placebo-controlled phase III trial of chemotherapy with or without bevacizumab in patients with platinum-sensitive recurrent epithelial ovarian, primary peritoneal, or fallopian tube cancer. J Clin Oncol. 2012 Jun 10;30(17):2039-45.
• [2] 2017 FDA drug approvals.Nat Rev Drug Discov. 2018 Feb;17(2):81-85.
• [3] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
• [4] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
• [5] ClinicalTrials.gov (NCT01727089) Bevacizumab With or Without TRC105 in Treating Patients With Metastatic Kidney Cancer. U.S. National Institutes of Health.
• [6] ClinicalTrials.gov (NCT01118052) EGEN-001 in Treating Patients With Persistent or Recurrent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer. U.S. National Institutes ofHealth.
• [7] ClinicalTrials.gov (NCT00617773) Hu3S193 in Treating Women With Ovarian Epithelial, Primary Peritoneal, or Fallopian Tube Cancer. U.S. National Institutes of Health.
• [8] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800027929)
• [9] ClinicalTrials.gov (NCT01335958) Safety and Pharmacokinetics of DMUC5754A Administered Intravenously to Patients With Platinum-Resistant Ovarian Cancer or Unresectable Pancreatic Cancer. U.S. National Institutes of Health.
• [10] ClinicalTrials.gov (NCT03054298) CAR T Cells in Mesothelin Expressing Cancers
• [11] ClinicalTrials.gov (NCT03608618) Intraperitoneal MCY-M11 (Mesothelin-targeting CAR) for Treatment of Advanced Ovarian Cancer and Peritoneal Mesothelioma. U.S. National Institutes of Health.
• [12] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
• [13] ClinicalTrials.gov (NCT02452775) Autologous OC-L Vaccine and Ovarian Cancer.
• [14] Results of annual screening in phase I of the United Kingdom familial ovarian cancer screening study highlight the need for strict adherence to screening schedule.J Clin Oncol. 2013 Jan 1;31(1):49-57. doi: 10.1200/JCO.2011.39.7638. Epub 2012 Dec 3.
• [15] Challenges in Interpreting Germline Mutations in BARD1 and ATM in Breast and Ovarian Cancer Patients.Breast J. 2017 Jul;23(4):461-464. doi: 10.1111/tbj.12764. Epub 2017 Jan 31.
• [16] The lack of clinical value of peritoneal washing cytology in high risk patients undergoing risk-reducing salpingo-oophorectomy: a retrospective study and review.BMC Cancer. 2016 Jan 14;16:18. doi: 10.1186/s12885-015-2011-5.